Sen. Grassley Wants GAO To Probe Surrogate-Endpoint Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Postmarket Avandia, Vytorin data spark demand for inquiry into FDA follow-up.
You may also be interested in...
Vytorin Fails To Show ENHANCEd Benefit Over Simvastatin In Plaque Reduction
Merck/Schering-Plough felt pressure to release findings earlier than its scheduled presentation at March American College of Cardiology meeting, Schering-Plough tells “The Pink Sheet” DAILY.
Avandia Expands Black Box With Heart Attack Risk Information
FDA revises labeling for all oral anti-diabetics to include warning about the absence of conclusive evidence of cardiovascular risk.
Avandia Should Stay On Market, Committee Says
Joint advisory committee concludes, however, that the thiazolidinedione raises cardiovascular risk.